Cytokine release syndrome, grade 3
ICD-10 D89.833 is a billable code used to indicate a diagnosis of cytokine release syndrome, grade 3.
Cytokine release syndrome (CRS) is a systemic inflammatory response that can occur following certain therapies, particularly those involving immunotherapy, such as CAR T-cell therapy or monoclonal antibodies. Grade 3 CRS is characterized by severe symptoms that may include high fever, hypotension, hypoxia, and significant organ dysfunction. Patients may experience elevated levels of inflammatory cytokines, leading to a cascade of immune responses that can affect multiple organ systems. The clinical presentation can vary widely, but common manifestations include respiratory distress, neurological symptoms, and coagulopathy. Management of grade 3 CRS often requires hospitalization and may involve supportive care, corticosteroids, and other immunomodulatory therapies. Accurate coding of CRS is essential for appropriate reimbursement and tracking of treatment outcomes, as it reflects the severity of the patient's condition and the complexity of care provided.
Detailed clinical notes on patient history, treatment regimen, and response to therapy.
Patients receiving CAR T-cell therapy or monoclonal antibodies who develop CRS.
Ensure clear documentation of CRS grading and management strategies.
Comprehensive records of vital signs, organ function assessments, and interventions.
Management of patients with severe CRS requiring intensive monitoring and treatment.
Accurate documentation of critical care interventions and their relation to CRS.
Used when administering chemotherapy that may lead to CRS.
Document the drug administered, dosage, and patient response.
Oncology specialists should ensure accurate coding of chemotherapy-related complications.
Common symptoms include high fever, hypotension, respiratory distress, neurological symptoms, and significant organ dysfunction. Patients may require intensive monitoring and treatment.
